View
218
Download
0
Category
Preview:
Citation preview
8/12/2019 M4 Safety Step 4 Sept02
1/113
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICALREQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
ICH HARMONISEDTRIPARTITEGUIDELINE
THECOMMONTECHNICALDOCUMENTFORTHEREGISTRATIONOFPHARMACEUTICALSFORHUMANUSE:
SAFETY M4S
NONCLINICALOVERVIEWANDNONCLINICALSUMMARIESOFMODULE2
ORGANISATIONOFMODULE4
Having reached Step 4 of the ICH Process at the ICH Steering Committeemeeting
on 9 November 2000, this guideline is recomm ended foradoption to the three regulatory parties to ICH
(Numbering and Section Headers have been edited for consistency and use in e-
CTD d t th W hi t DC M ti S t b 11 12 2002)
8/12/2019 M4 Safety Step 4 Sept02
2/113
CTD as agreed at the Washington DC Meeting September 11 12 2002)
The Common Technical Document - Safety
THECOMMONTECHNICALDOCUMENTFORTHEREGISTRATIONOFPHARMACEUTICALSFORHUMANUSE:
SAFETY
NONCLINICALOVERVIEWANDNONCLINICALSUMMARIESOFMODULE2
ORGANISATIONOFMODULE4
ICH Harmonised Tripartite Guideline
Having reachedStep 4
of the ICH Process at the ICH Steering Committeemeeting
on 9 November 2000, this guideline is recomm ended for
adoption to the three regulatory parties to ICH(Numbering and Section Headers have been edited for consistency and use in e-
CTD as agreed at the Washington DC Meeting, September 11-12, 2002)
TABLE OF CONTENTS
(This document includes the typographic correction on page 46 : to readpoint 2.6.7.3, agreed by the Steering Committee on 20December 2002) . ...................................................................................i
Module 2 : Common Technical Document Summaries ....................................1
General Principles of Nonclinical Overview and Summaries .....................................1
8/12/2019 M4 Safety Step 4 Sept02
3/113
The Common Technical Document - Safety
2.6.4.1 Brief Summary .......................................................................................... 7
2.6.4.2 Methods of Analysis..................................................................................7
2.6.4.3 Absorption ..................................................................................................7
2.6.4.4 Distribution................................................................................................7
2.6.4.5 Metabolism (interspecies comparison) .................................................7
2.6.4.6 Excretion ....................................................................................................7
2.6.4.7 Pharmacokinetic Drug Interactions .......................................................7
2.6.4.8 Other Pharmacokinetic Studies ..............................................................8
2.6.4.9 Discussion and Conclusions ....................................................................8
2.6.4.10 Tables and Figures.................................................................................8
2.6.5 Pharmacokinetics Tabulated Summary (see Appendix B)...............................8
2.6.6 Toxicology Written Summary ...............................................................................8
2.6.6.1 Brief Summary .......................................................................................... 8
2.6.6.2 Single-Dose Toxicity .................................................................................9
2.6.6.3 Repeat-Dose Toxicity (including supportive toxicokineticsevaluation).............................................................................................9
2.6.6.4 Genotoxicity ...............................................................................................9
2.6.6.5 Carcinogenicity (including supportive toxicokinetics evaluations) . .9
2 6 6 6 R d ti d D l t l T i it (i l di g g fi di g
8/12/2019 M4 Safety Step 4 Sept02
4/113
The Common Technical Document - Safety
MODULE2 : COMMONTECHNICALDOCUMENTSUMMARIES
General Principles of Nonclinical Overview and Summaries
This guideline provides recommendations for the harmonisation of the NonclinicalOverview, Nonclinical Written Summary, and Nonclinical Tabulated Summaries.
The primary purpose of the Nonclinical Written and Tabulated Summaries should be toprovide a comprehensive factual synopsis of the nonclinical data. The interpretation ofthe data, the clinical relevance of the findings, cross- linking with the quality aspects ofthe pharmaceutical, and the implications of the nonclinical findings for the safe use of
the pharmaceutical (i.e., as applicable to labeling) should be addressed in theOverview.
2.4 NONCLINICAL OVERVIEW
The Nonclinical Overview should provide an integrated overall analysis of theinformation in the Common Technical Document. In general, the Nonclinical Overviewshould not exceed about 30 pages.
General AspectsThe Nonclinical Overview should present an integrated and critical assessment of thepharmacologic, pharmacokinetic, and toxicologic evaluation of the pharmaceutical.Where relevant guidelines on the conduct of studies exist, these should be taken intoconsideration, and any deviation from these guidelines should be discussed and
justified. The nonclinical testing strategy should be discussed and justified. Thereshould be comment on the GLP status of the studies submitted. Any associationbetween nonclinical findings and the quality characteristics of the human
h ti l th lt f li i l t i l ff t ith l t d d t
8/12/2019 M4 Safety Step 4 Sept02
5/113
The Common Technical Document - Safety
Content and Structural Format
The Nonclinical Overview should be presented in the following sequence :
Overview of the nonclinical testing strategyPharmacology
Pharmacokinetics
Toxicology
Integrated overview and conclusions
List of literature references
Studies conducted to establish the pharmacodynamic effects, the mode of action, and
potential side effects should be evaluated and consideration should be given to thesignificance of any issues that arise.
The assessment of the pharmacokinetic, toxicokinetic, and metabolism data shouldaddress the relevance of the analytical methods used, the pharmacokinetic models,and the derived parameters. It might be appropriate to cross-refer to more detailedconsideration of certain issues within the pharmacology or toxicology studies (e.g.impact of the disease states, changes in physiology, anti-product antibodies, cross-species consideration of toxicokinetic data). Inconsistencies in the data should be
discussed. Inter-species comparisons of metabolism and systemic exposurecomparisons in animals and humans (AUC, Cmax, and other appropriate parameters)should be discussed and the limitations and utility of the nonclinical studies forprediction of potential adverse effects in humans highlighted.
The onset, severity, and duration of the toxic effects, their dose-dependency anddegree of reversibility (or irreversibility), and species- or gender-related differencesshould be evaluated and important features discussed, particularly with regard to:
h d i
8/12/2019 M4 Safety Step 4 Sept02
6/113
The Common Technical Document - Safety
The evaluation of toxicology studies should be arranged in a logical order so that allrelevant data elucidating a certain effect / phenomenon are brought together.Extrapolation of the data from animals to humans should be considered in relation to:
animal species used
numbers of animals used
routes of administration employed
dosages used
duration of treatment or of the study
systemic exposures in the toxicology species at no observed adverse effectlevels and at toxic doses, in relation to the exposures in humans at themaximum recommended human dose. Tables or figures summarising thisinformation are recommended.
the effect of the drug substance observed in nonclinical studies in relation to
that expected or observed in humans
If alternatives to whole-animal experiments are employed, their scientific validityshould be discussed.
The Integrated Overview and Conclusions should clearly define the characteristics ofthe human pharmaceutical as demonstrated by the nonclinical studies and arrive atlogical, well-argued conclusions supporting the safety of the product for the intendedclinical use. Taking the pharmacology, pharmacokinetics, and toxicology results intoaccount, the implications of the nonclinical findings for the safe human use of thepharmaceutical should be discussed (i.e., as applicable to labeling).
2.6 NONCLINICAL WRITTEN AND TABULATED SUMMARIES
8/12/2019 M4 Safety Step 4 Sept02
7/113
The Common Technical Document - Safety
General Presentation Issues
Order of Presentation of Information within Sections
When available, in vitro studies should precede in vivo studies.
Where multiple studies of the same type need to be summarised within thePharmacokinetics and Toxicology sections, studies should be ordered by species, byroute, and then by duration (shortest duration first).
Species should be ordered as follows:
Mouse
Rat
Hamster
Other rodent
Rabbit
Dog
Non-human primate
Other non-rodent mammal
Non-mammals
Routes of administration should be ordered as follows :
The intended route for human use
Oral
Intravenous
8/12/2019 M4 Safety Step 4 Sept02
8/113
The Common Technical Document - Safety
Length of Nonclinical Written Summaries
Although there is no formal limit to the length of the Nonclinical Written Summaries, itis recommend ed that the total length of the three Nonclinical Written Summaries ingeneral not exceed 100-150 pages.
Sequence of Written Summaries and Tabulated Summaries
The following order is recommended:
Introduction
Written Summary of Pharmacology
Tabulated Summary of Pharmacology
Written Summary of Pharmacokinetics
Tabulated Summary of Pharmacokinetcs
Written Summary of Toxicology
Tabulated Summary of Toxicology
Content of Nonclinical Written and Tabulated Summaries
2.6 .1 Introduction
The aim of this section should be to introduce the reviewer to the pharmaceutical andto its proposed clinical use. The following key elements should be covered:
Brief information concerning the pharmaceuticals structure (preferably, a
structure diagram should be provided) and pharmacologic properties.
I f ti i th h ti l d li i l i di ti d
8/12/2019 M4 Safety Step 4 Sept02
9/113
The Common Technical Document - Safety
2.6.2.2 Primary Pharmacodynamics
Studies on primary pharmacodynamics* should be summarised and evaluated. Wherepossible, it would be helpful to relate the pharmacology of the drug to available data
(in terms of selectivity, safety, potency, etc.) on other drugs in the class.
2.6.2.3 Secondary Pharmacodynamics
Studies on secondary pharmacodynamics* should be summarised by organ system,where appropriate, and *evaluated in this section.
2.6.2.4 Safety Pharmacology
Safety pharmacology studies* should be summarised and evaluated in this section. In
some cases, secondary pharmacodynamic studies can contribute to the safetyevaluation when they predict or assess potential adverse effect(s) in humans. In suchcases, these secondary pharmacodynamic studies should be considered along withsafety pharmacology studies.
2.6.2.5 Pharmacodynamic Drug Interactions
If they have been performed, pharmacodynamic drug interaction studies should bebriefly summarised in this section.
2.6.2.6 Discussion and Conclusions
This section provides an opportunity to discuss the pharmacologic evaluation and toconsider the significance of any issues that arise.
2.6.2.7 Tables and Figures
Text tables and figures can be included at appropriate points throughout the summarywithin the text. Alternatively, tables and figures can be included at the end of the
8/12/2019 M4 Safety Step 4 Sept02
10/113
The Common Technical Document - Safety
2.6.4.1 Brief Summary
The principal findings from the pharmacokinetics studies should be briefly summarizedin approximately 2 to 3 pages. This section should begin with a description of the
scope of the pharmacokinetic evaluation, emphasising, for example, whether thespecies and strains examined were those used in the pharmacology and toxicologyevaluations, and whether the formulations used were similar or identical.
2.6.4.2 Methods of Analysis
This section should contain a brief summary of the methods of analysis for biologicalsamples, including the detection and quantification limits of an analytical procedure. Ifpossible, validation data for the analytical method and stability of biological samples
should be discussed in this section. The potential impact of different methods ofanalysis on the interpretation of the results should be discussed in the followingrelevant sections.
2.6.4.3 Absorption
The following data should be summarised in this section:
Absorption (extent and rate of absorption, in vivo and in situ studies)
Kinetic parameters, bioequivalence and/or bioavailability (serum/plasma/blood
PK studies)
2.6.4.4 Distribution
The following data should be summarised in this section:
Tissue distribution studies
Protein binding and distribution in blood cells
Pl t l t f t di
8/12/2019 M4 Safety Step 4 Sept02
11/113
The Common Technical Document - Safety
2.6.4.8 Other Pharmacokinetic Studies
If studies have been performed in nonclinical models of disease (e.g., renally impairedanimals), they should be summarised in this section.
2.6.4.9 Discussion and Conclusions
This section provides an opportunity to discuss the pharmacokinetic evaluation and toconsider the significance of any issues that arise.
2.6.4.10 Tables and Figures
Text tables and figures can be included at appropriate points throughout the summarywithin the text. Alternatively, there is the option of including tables and figures at the
end of the summary.
2.6.5 Pharmacokinetics Tabulated Summary (see Appendix B)
2.6.6 Toxicology Written Summary
The sequence of the Toxicology Written Summary should be as follows:
Brief Summary
Single-Dose Toxicity
Repeat-Dose Toxicity
Genotoxicity
Carcinogenicity
Reproductive and Developmental Toxicity
Studies in Juvenile Animals
8/12/2019 M4 Safety Step 4 Sept02
12/113
The Common Technical Document - Safety
TOXICOLOGY PROGRAMME
Study type andduration
Route ofadministration
Species Compoundadministered*
Single-dosetoxicitySingle-dosetoxicityRepeat-dosetoxicity
1 month
6 months9 months,etc.
po and ivpo and iv
popopo
Rat and mouseRat and mouse
Rat and dogRatDog
Parent drugMetabolite X
Parent drug
* This column required only if metabolite(s) are investigated.
The scope of the toxicologic evaluation should be described in relation to the proposedclinical use. A comment on the GLP status of the studies should be included.
2.6.6.2 Single- Dose Toxicity
The single-dose data should be very briefly summarised, in order by species, by route.In some instances, it may be helpful to provide the data in the form of a table.
2.6.6.3 Repeat- Dose Toxicity (including supportive toxicokinetics evaluation)
Studies should be summarised in order by species, by route, and by duration, givingbrief details of the methodology and highlighting important findings (e.g., nature and
it f t t t i it d ( )/ l ti hi b d
8/12/2019 M4 Safety Step 4 Sept02
13/113
The Common Technical Document - Safety
Other studies
2.6.6.6 Reproductiv e and Developmental Toxicity (including range- finding studies andsupportive toxicokinetics evaluations)
Studies should be summarised in the following order, giving brief details of themethodology and highlighting important findings:
Fertility and early embryonic development
Embryo-fetal development
Prenatal and postnatal development, including maternal function
Studies in which the offspring (juvenile animals) are dosed and/or furtherevaluated, if such studies have been conducted.
If modified study designs are used, the sub-headings should be modified accordingly.
2.6.6.7 Local Tolerance
If local tolerance studies have been performed, they should be summarised in order byspecies, by route, and by duration, giving brief details of the methodology andhighlighting important findings.
2.6.6.8 Other Toxicity Studies (if available)
If other studies have been performed, they should be summarised. When appropriate,the rationale for conducting the studies should be provided.
Antigenicity
Immunotoxicity
Mechanistic studies (if not reported elsewhere)
8/12/2019 M4 Safety Step 4 Sept02
14/113
The Common Technical Document - Safety
can modify the format if needed to provide the best possible presentation of theinformation and to facilitate the understanding and evaluation of the results.
This Guideline is not intended to indicate what studies are requested, but solely to
advise how to tabulate study results if a study is performed. Applicants might need toadd some items to or delete some items from the cited format where appropriate. Onetabular format can contain results from several studies. Alternatively, it may beappropriate to cite the data resulting from one study in several tabular formats.
The recommende d formats for the tables in the Nonclinical Tabulated Summaries areprovided in Appendices B and C, which follow. Appendix B contains templates for usein preparation of the tables. The templates are annotated (in italics) to provideguidance on their preparation. (The italicized information should be deleted when the
tables are prepared.) Appendix C provides examples of the summary tables. Thepurpose of the examples is to provide additional guidance on the suggested contentand format of the Tabulated Summaries. However, it is the responsibility of theapplicant to decide on the best possible presentation of the data for each product.
Authors should keep in mind that, in some regions, a review of the TabulatedSummaries (in conjunction with the Written Summaries) represents the primary reviewof the nonclinical information. Presentation of the data in the formats provided astemplates and examples should ensure that a sufficient level of detail is available to
the reviewer and should provide concise overviews of related information.When a juvenile-animal study has been conducted, it should be tabulated using thetemplate appropriate for the type of study.
The order of presentation given for the Nonclinical Written Summaries should befollowed for the preparation of the tables for the Nonclinical Tabulated Summaries.
8/12/2019 M4 Safety Step 4 Sept02
15/113
The Common Technical Document - Safety
MODULE4: NONCLINICALSTUDYREPORTSThis guideline presents an agreed format for the organisation of the nonclinical reportsin the Common Technical Document for applications that will be submitted toRegulatory Authorities. This guideline is not intended to indicate what studies arerequired. It merely indicates an appropriate format for the nonclinical data that havebeen acquired.
The appropriate location for individual-animal data is in the study report or as anappendix to the study report.
4.1 Table of Contents of Module 4
A Table of Contents should be provided that lists all of the nonclinical study reportsand gives the location of each study report in the Common Technical Document.
4.2 Study Reports
The study reports should be presented in the following order:
4.2.1 Pharmacology
4.2.1.1 Primary Pharmacodynamics
4.2.1.2 Secondary Pharmacodynamics
4.2.1.3 Safety Pharmacology
4.2.1.4 Pharmacodynamic Drug Interactions
4.2.2 Pharmacokinetics
4.2.2.1 Analytical Methods and Validation Reports (if separate reports areavailable)
4 2 2 2 Ab ti
8/12/2019 M4 Safety Step 4 Sept02
16/113
The Common Technical Document - Safety
4.2.3.4.2 Short- or medium-term studies (including range-findingstudies that cannot appropriately be included under repeat-dose toxicity or pharmacokinetics)
4.2.3.4.3 Other studies
4.2.3.5 Reproductive and Developmental Toxicity (including range- findingstudies and supportive toxicokinetics evaluations) (If modified studydesigns are used, the following sub-headings should be modifiedaccordingly.)
4.2.3.5.1 Fertility and early embryonic development
4.2.3 .5.2 Embryo-fetal development
4.2.3 .5.3 Prenatal and postnatal development, including maternalfunction
4.2.3 .5.4 Studies in which the offspring (juvenile animals) are dosedand/or further evaluated.
4.2.3.6 Local Tolerance
4.2.3.7 Other Toxicity Studies (if available)
4.2.3 .7.1 Antigenicity
4.2.3.7.2 Immunotoxicity
4.2.3 .7.3 Mechanistic studies (if not included elsewhere)
4.2.3.7.4 Dependence
4.2.3.7.5 Metabolites
4.2.3.7.6 Impurities
8/12/2019 M4 Safety Step 4 Sept02
17/113
The Common Technical Document - Safety
APPENDIXA
Examples of Tables and Figures for Written Summaries
The tables and figures in Appendix A are presented merely as examples. Applicantsshould provide tables and figures using a format appropriate to the product.
Study references should be included in the table or text.
Tables should include statistics, if appropriate.
8/12/2019 M4 Safety Step 4 Sept02
18/113
The Common Technical Document - Safety
Table X
Binding of X and its Major Metabolites and Comparators
to Human X2and X3Receptors
Compound X2
Ki1(nM)
X2
Ki2(nM)
X3
Ki1(nM)
X3
Ki2(nM)
1 538 2730 691 4550
2 2699 1050 2.0 181
3 578 14.4 141 10400
4 20 100 10.7 7.9
5 2100 3.1 281 28
6 7.5 8.4 44 2.8
7 3.11 3.76 1.94 1.93
Ki1 and Ki2 represent the high and low affinity binding sites respectively (Data from Study Number).
8/12/2019 M4 Safety Step 4 Sept02
19/113
The Common Technical Document - Safety
Figure X
Blood pressure following chronic dosing with X to SHRa
8/12/2019 M4 Safety Step 4 Sept02
20/113
The Common Technical Document - Safety
Table X
Model-independent pharmacokinetic parameters for X in mice following single oral doses at 2,
10 and 30 mg/kg [ref]
Parameter
(units)
Parameter value
Sex Males Females
Dose(mg/kg)
2 10 30 2 10 30
Cmax(ng/mL)
4.9 20.4 30.7 5.5 12.9 28.6
Tmax(h) 0.8 0.4 0.3 0.4 0.5 0.3
AUC0-t(ng.h/mL)
21.6 80.5 267 33.3 80 298
AUC0-inf(ng.h/mL)
28.3 112 297 40.2 90 327
Pharmacokinetic parameters were determined in pooled plasma from three animals at eachtime
8/12/2019 M4 Safety Step 4 Sept02
21/113
The Common Technical Document - Safety
Table X
Concentrations of radioactive material in the tissues of male rats after a single intravenousdose of [14C]X at 1.75 mg/kg [refs]
Tissue Concentration (ng equiv.*/g)
1 h 6 h 24 h 48 h 72 h
Blood 105 96.6 2.34 2.34 3.65
Plasma 142 175 3.12 ND ND
Adrenals 656 49.2 14.3 9.63 ND
Bone
marrow
359 31.5 ND ND ND
Brain 116 9.37 ND ND ND
Eyes 124 28.9 4.69 ND ND
Fat 490 44.0 10.2 6.25 5.47
Heart 105 26.6 ND ND ND
8/12/2019 M4 Safety Step 4 Sept02
22/113
The Common Technical Document - Safety
Table X
Excretion of radioactive material following single doses of [14C]X to male rats [refs]
Dose (mg/kg)/ Percentage of administered dose
route Urine Faeces Bile Total
1.75 i.v. 61.3 9.3 30.3 4.1 - 95.2 5.0
1.75 p.o. 57.4 3.8 37.0 3.4 - 95.2 1.5
2 p.o. 72.3 0.8 26.9 1.9 - 99.5 1.1
20 p.o. 23.5 6.3 0.5 0.2 76.0 5.9 100 0.8
220 p.o. 67.1 9.0 24.8 5.0 - 93.3 6.8
Excretion was determined over 168 h period in Wistar rats:Values are means S.D.(n=5); - not assayed; Total includes radioactivity in the carcass and cage washings
8/12/2019 M4 Safety Step 4 Sept02
23/113
The Common Technical Document - Safety
Table X
Comparative pharmacokinetic data and systemic exposure to X following oral administration to mice, rats, dogs and
patients [ref]
Species (formulation) Dose (mg/kg/day) Systemic (plasma) exposure References
Cmax
(ng/mL)
AUC (ng.h/mL)#
Man (tablet) 0.48$ 36.7 557 X
Mouse (solution) 8.8 68.9 (1.9)* 72.7 (0.2)* Y
21.9 267 (7.3)* 207 (0.5)*
43.8 430 (11.7)* 325 (0.7)*
Rat (solution) 50 479 (13.0)* 1580 (2.8)* Z
Dogs (solution) 1.5 5.58 (0.2)* 15.9 (
8/12/2019 M4 Safety Step 4 Sept02
24/113
The Common Technical Document - Safety
Table X
Incidence of Proliferative Interstitial (Leydig) Cell Lesions in Rats [ref]
Dose Groups
Lesion Control 3 mg/kg 30 mg/kg 100 mg/kg
Hyperplasia(only)
x/50 (%) x/50 (%) x/50 (%) x/50 (%)
Adenoma(only)
x/50 (%) x/50 (%) x/50 (%) x/50 (%)
Adenoma +Hyperplasia
x/50 (%) x/50 (%) x/50(%) x/50 (%)
Total* x/50 (%) x/50 (%) x/50 (%) x/50 (%)
* Adenoma and/or Hyperplasia
8/12/2019 M4 Safety Step 4 Sept02
25/113
The Common Technical Document - Safety
APPENDIXB
The Nonclinical Tabulated Summaries - Templates
8/12/2019 M4 Safety Step 4 Sept02
26/113
The Common Technical Document - Safety
The Nonclinical Tabulated Summaries Templates
2.6.3 Pharmacology
2.6.3 .1 Pharmacology : Overview
2.6.3.2 Primary Pharmacodynamics *
2.6.3 .3 Secondary Pharmacodynamics*
2.6.3 .4 Safety Pharmacology
2.6.3.5 Pharmacodynamic Drug Interactions*
2.6.5 Pharmacokinetics
2.6.5.1 Pharmacokinetics: Overview
2.6.5.2 Analytical Methods and Validation Reports*
2.6.5.3 Pharmacokinetics: Absorption after a Single Dose
2.6.5.4 Pharmacokinetics: Absorption after Repeated Doses
2.6.5.5 Pharmacokinetics: Organ Distribution
2.6.5.6 Pharmacokinetics: Plasma Protein Binding
2.6.5.7 Pharmacokinetics: Study in Pregnant or Nursing Animals
2.6.5.8 Pharmacokinetics: Other Distribution Study
8/12/2019 M4 Safety Step 4 Sept02
27/113
The Common Technical Document - Safety
2.6.7.6 Repeat-Dose Toxicity: Non-Pivotal Studies
2.6.7.7 Repeat-Dose Toxicity: Pivotal Studies
2.6.7.8 Genotoxicity: In Vitro2.6.7.9 Genotoxicity: In Vivo
2.6.7.10 Carcinogenicity
2.6.7.11 Reproductive and Developmental Toxicity: Non-Pivotal Studies
2.6.7.12 Reproductive and Developmental Toxicity Fertility and EarlyEmbryonic Development to Implantation (Pivotal)
2.6.7.13 Reproductive and Developmental Toxicity Effects on Embryo-Fetal Development (Pivotal)
2.6.7.14 Reproductive and Developmental Toxicity Effects on Pre- andPostnatal Development, Including Maternal Function (Pivotal)
2.6.7.15 Studies in Juvenile Animalsa
2.6.7.16 Local Tolerance
2.6.7.17 Other Toxicity Studies
* : Tabulated Summary is optional. It is preferable to include text tables and figureswith the Nonclinical Written Summary.
a: When a juvenile animal study has been conducted, it should be tabulatedusing the template appropriate for the type of study and located inSection 2.6.7.15.
8/12/2019 M4 Safety Step 4 Sept02
28/113
The Common Technical Document - Safety
2.6.3.1 Pharmacology Overview Test Article: (1)
Type of StudyTestSystem
Method ofAdmiistratio
Testig!acility
Study"um#er(4)
$ocatio%ol. Sectio
Primary Pharmacodyamics (2)
(3)
Secodary Pharmacodyamics
Safety Pharmacology
Pharmacodyamic &rug 'teractios
Notes: (1) International Nonproprietary Name (INN)(2) There should be one line for each pharmacology report, in the same order as the CT! "eports that contain a #$% Compliance
&tatement should be identified in a footnote!(3) T he location of the Technical "eport in the CT should be indicated!(4) 'r "eport Number (on all tables)!
8/12/2019 M4 Safety Step 4 Sept02
29/113
The Common Technical Document - Safety
2.6.3.( Safety Pharmacology(1) Test Article)(2)
OrgaSystems*valuated
Species+Strai
Method ofAdmi.
&osesa
,mg+-g
/ederad "o.per /roup "oteworthy !idigs
GLP0ompliace
Study"um#er,3)
Notes: (1) ll safetypharmacology studies should be summari*ed!(2) International Nonproprietary Name (INN)!(3) 'r "eport Number (on all tables)!
a - Single dose unless specified otherwise.
8/12/2019 M4 Safety Step 4 Sept02
30/113
The Common Technical Document - Safety
2.6..1 Pharmaco-ietics Overview Test Article)(1)
Type of StudyTestSystem
Method ofAdmiistratio
Testig!acility
Study"um#er
$ocatio%ol.Sectio
A#sorptio (2)
(3)
&istri#utio
Meta#olism
*cretio
Pharmaco-ietic &rug 'teractios
Other
Notes: (1) International Nonproprietary Name (INN)!(2) There should be one line for each pharmaco+inetics report, in the same order as the CT! "eports that contain a #$% Compliance
&tatement should be identified in a footnote!(3) The location of the Technical "eport in the CT should be indicated!
8/12/2019 M4 Safety Step 4 Sept02
31/113
The Common Technical Document - Safety
2.6..3 Pharmaco-ietics) A#sorptio after a Sigle &ose Test Article)(1)$ocatio i 0T&) Vol. SectionStudy "o.
Species __________ __________ __________ __________ _________/eder ,M+! + "um#er of aimals (4)
!eedig coditio%ehicle+!ormulatioMethod of Admiistratio&ose ,mg+-gSample ,hole #lood4 plasma4 serum etc.AalyteAssay (2)P5 parameters)
Additioal 'formatio) (3)
Notes: (1) International Nonproprietary Name (INN)!(2) or e-ample, .%$C, $&C /ith 10Clabeled compound!(3) or e-ample, brief te-tual results, species differences, gender differences, dose dependency, or special comments!(4) There should be one column for each study conducted! or comparison, representatie information on humans at the ma-imum recommended dose should be included!
8/12/2019 M4 Safety Step 4 Sept02
32/113
The Common Technical Document - Safety
2.6..( Pharmaco-ietics) A#sorptio after epeated &oses Test Article)
ata may be tabulated as in the format of 2!!4!3 if applicable!5
8/12/2019 M4 Safety Step 4 Sept02
33/113
The Common Technical Document - Safety
Format A
2.6.. Pharmaco-ietics) Orga &istri#utio Test Article)$ocatio i 0T&) Vol. SectionStudy "o.
Species)
/eder ,M+!+"um#er of aimals)!eedig coditio)%ehicle+!ormulatio)Method of Admiistratio)&ose ,mg+-g)adiouclide)Specific Activity)Samplig time)
0ocetratio ,uit
Tissues+orgas T,1 T,2 T,3 T,( T, t1+2
Additioal iformatio)
8/12/2019 M4 Safety Step 4 Sept02
34/113
The Common Technical Document - Safety
Alternate Format B
2.6.. Pharmaco-ietics) Orga &istri#utio Test Article)$ocatio i 0T&) Vol. SectionStudy "o.
Species)/eder ,M+! + "um#er of aimals)!eedig coditio)
%ehicle+!ormulatio)Method of Admiistratio)&ose ,mg+-g)adiouclide)Specific Activity)Aalyte+Assay ,uit)Samplig time)
0t $ast time7poitTissues+orgas coc. T+P1 coc. T+P1 Time A80 t1+2
Additioal iformatio)
19Tissue:+9Plasma:
8/12/2019 M4 Safety Step 4 Sept02
35/113
The Common Technical Document - Safety
2.6..6 Pharmaco-ietics) Plasma Protei ;idig Test Article)
Study system)Target etity4 Test system ad method)
Species 0oc. tested < ;oud
Study
"o.
$ocatio i 0T&
%ol. Sectio
Additioal 'formatio)
8/12/2019 M4 Safety Step 4 Sept02
36/113
The Common Technical Document - Safety
2.6..= Pharmaco-ietics) Study i Pregat or "ursig Aimals (1) Test Article) (2)$ocatio i 0T&) Vol. Section
Placetal trasfer Study "o.Species)/estatio day + "um#er of aimals)
%ehicle+!ormulatio)Method of Admiistratio)&ose ,mg+-g)Aalyte)Assay)Time ,hr __________ _________ _________ __________ __________0ocetratio + Amout ,< of dose &am (3)) !etus (3))
Additioal 'formatio)
$ocatio i 0T&) Vol. Section
*cretio ito mil- Study "o.Species)$actatig date + "um#er of aimals)!eedig coditio)%ehicle+!ormulatio)Method of Admiistratio)&ose ,mg+-g)Aalyte)Assay)Time 9hr: __________ __________ __________ __________ __________0ocetratio) Mil-)
Plasma) Mil- + plasma) "eoates)
Additioal 'formatio)
8/12/2019 M4 Safety Step 4 Sept02
37/113
The Common Technical Document - Safety
"otes for Ta#le 2.6..=
(1) Even if the data are obtained in reproduction toxicolog studies! the should be presented in this table.(2) "nternational #onproprietar #a$e ("##).(3) %he tissue sa$pled should be described& e.g.! plas$a for da$s! fetal concentrations.
8/12/2019 M4 Safety Step 4 Sept02
38/113
The Common Technical Document - Safety
2.6..> Pharmaco-ietics) Other &istri#utio Study Test Article)
8/12/2019 M4 Safety Step 4 Sept02
39/113
The Common Technical Document - Safety
2.6..? Pharmaco-ietics) Meta#olismIn Vivo Test Article)
/eder,M+! + "um#er of aimals)!eedig coditio)%ehicle+!ormulatio)Method of Admiistratio)&ose ,mg+-g)
adiouclide)Specific Activity)
< of 0ompoud i Sample $ocatio i 0T&
Species SampleSamplig Time or Period
< of &osei Sample Paret M1 M2
Study "o. %ol Sectio
'las$arineile*eces
'las$arineile*eces
'las$arineile*eces
Additioal 'formatio)
#ote: .uman data should be included for comparison, if aailable!
8/12/2019 M4 Safety Step 4 Sept02
40/113
The Common Technical Document - Safety
2.6..1@ Pharmaco-ietics) Meta#olism In Vitro Test Article)$ocatio i 0T&) Vol. SectionStudy "o.
Study system)
Time __________ __________ __________ __________ __________0ocetratio)0ompouds Paret M71 M72
Additioal 'formatio)
Note: .uman data should be included for comparison, if aailable!
8/12/2019 M4 Safety Step 4 Sept02
41/113
The Common Technical Document - Safety
2.6..11 Pharmaco-ietics) Possi#le Meta#olic Pathways Test Article)
(Illustrate possible metabolic map indicating species in /hich metabolic reactions occur!)
8/12/2019 M4 Safety Step 4 Sept02
42/113
The Common Technical Document - Safety
2.6..12 Pharmaco-ietics) 'ductio+'hi#itio of &rug7Meta#oliig *ymes Test Article)$ocatio i 0T&) Vol. SectionStudy "o.
Note: Nonclinical studies only!
Type of study)
Method)
Ta#ulated results)
Additioal 'formatio)
8/12/2019 M4 Safety Step 4 Sept02
43/113
The Common Technical Document - Safety
2.6..13 Pharmaco-ietics) *cretio Test Article) (1)
Species __________ __________ __________ _________
/eder ,M+! + "um#er of aimals (3)
!eedig coditio
%ehicle+!ormulatio
Method of Admiistratio
&ose ,mg+-g
Aalyte
Assay
*cretio route (4) 8rie !eces Total 8rie !eces Total 8rie !eces Total 8rie !eces Total Time @ 7 T hr
Study um#er
$ocatio i 0T&
Additioal 'formatio) (2)
Notes: (1) International Nonproprietary Name (INN)!(2) or e-ample, brief te-tual results, species differences, gender differences, dose dependency, or special comments!(3) There should be one column for each study conducted! or comparison, representatie information on humans at the ma-imum
recommended dose should be included! 6ay be combined /ith the bsorption Table, if appropriate!(4) 'ther routes (e!g!, biliary, respiratory) should be added, if performed!
8/12/2019 M4 Safety Step 4 Sept02
44/113
The Common Technical Document - Safety
2.6.5.14 Pharmacokinetic! "#cretion into Bile $et Article!
ata may be tabulated as in the format of 2!!4!13 if applicable!5
8/12/2019 M4 Safety Step 4 Sept02
45/113
The Common Technical Document - Safety
2.6..1 Pharmaco-ietics) &rug7&rug 'teractios Test Article)$ocatio i 0T&) Vol. SectionStudy "o.
Type of study)
Method)
Ta#ulated results)
Additioal 'formatio)
8/12/2019 M4 Safety Step 4 Sept02
46/113
The Common Technical Document - Safety
2.6.5.16 Pharmacokinetic! %ther Test Article)$ocatio i 0T&) Vol. SectionStudy "o.
Type of study)
Method)
Ta#ulated results)
Additioal 'formatio)
8/12/2019 M4 Safety Step 4 Sept02
47/113
The Common Technical Document - Safety
2.6.=.1 Toicology Overview Test Article) (1)
Type of StudySpecies adStrai
Method ofAdmiistratio
&uratioof &osig &oses ,mg+-ga
/$P0ompliac
e
Testig!acility
Study"um#er
$ocatio%ol.
Sectio
Sigle7&oseToicity
(2) (3)
epeat7&oseToicity
/eotoicity
0arciogeicity
eproductive ad&evelopmetalToicity
$ocal Tolerace
OtherToicity Studies
Notes: (1) International Nonproprietary Name (INN)!(2) There should be one line for each to-icology report, in the same order as the CT!(3) The location of the Technical "eport in the CT should be indicated!
a - nless otherwise specified. *or +epeat-,ose %oxicit! the highest #E/ (#o bserved dverse-Effect /evel) is underlined.
8/12/2019 M4 Safety Step 4 Sept02
48/113
The Common Technical Document - Safety
2.6.=.2 Toico-ietics Overview of Toico-ietics Studies Test Article) (1)
Type of StudyTestSystem
Method ofAdmiistratio &oses ,mg+-g
/$P0ompliace
Study"um#er
$ocatio%ol.Sectio
(2) (3)
Notes: (1) International Nonproprietary Name (INN)!(2) There should be one line for each to-ico+inetics report, in the same order as the CT (&ection 3, To-icology)!(3) The location of the Technical "eport in the CT should be indicated!
8/12/2019 M4 Safety Step 4 Sept02
49/113
The Common Technical Document - Safety
2.6.=.3 Toico-ietics Overview of Toico-ietics &ata Test Article) (1)
(2)
Notes: (1) International Nonproprietary Name (INN)!(2) one to threepage summary (tables and7or figures) of steadystate to-ico+inetic data should be prepared in a format that facilitates
comparisons across species, including humans!
8/12/2019 M4 Safety Step 4 Sept02
50/113
The Common Technical Document - Safety
2.6.=.( Toicology &rug Su#stace Test Article) (1)
;atch "o. Purity ,
8/12/2019 M4 Safety Step 4 Sept02
51/113
The Common Technical Document - Safety
2.6.=. Sigle7&ose Toicity (1) Test Article)(2)
Species+Strai
Method ofAdmiistratio,%ehicle+!ormulatio
&oses,mg+-g
/ederad "o.per /roup
O#servedMaimum "o7$ethal &ose,mg+-g
Approimate$ethal&ose ,mg+-g "oteworthy !idigs
Study"um#er
Notes: (1)ll singledose to-icity studies should be summari*ed, in the same order as the CT! ootnotes should be used to indicate specialfeatures, such as unusual duration, infusion rate, or age of test sub8ects!
(2) International Nonproprietary Name (INN)!
8/12/2019 M4 Safety Step 4 Sept02
52/113
The Common Technical Document - Safety
2.6.=.6 epeat7&ose Toicity "o7Pivotal Studies(1) Test Article)(2)
Species+Strai
Method ofAdmiistratio,%ehicle+
!ormulatio
&uratioof &osig
&oses,mg+-g
/ederad "o.per /roup
"OA*$a
,mg+-g "oteworthy !idigsStudy"um#er
Notes: (1) ll repeatdose to-icity studies (including all rangefinding to-icity studies), other than the definitie #$% studies specified by IC.
#uideline 63, should be summari*ed, in the same order as the CT! ootnotes should be used to indicate special features, such asunusual age of test sub8ects!
(2) International Nonproprietary Name (INN)!
________a - #o bserved dverse-Effect /evel.
8/12/2019 M4 Safety Step 4 Sept02
53/113
The Common Technical Document - Safety
2.6.=.= (1)epeat7&ose Toicity(2) eport Title) Test Article)(3)
Species+Strai) &uratio of &osig) Study "o.'itial Age) &uratio of Postdose) $ocatio i 0T&)Vol. Section&ate of !irst &ose) Method of Admiistratio)
%ehicle+!ormulatio) /$P 0ompliace)
Special !eatures)"o O#served Adverse7*ffect $evel)
&aily &ose ,mg+-g (0ontrol)"um#er of AimalsToico-ietics) A80 , (4)"oteworthy !idigs&ied or Sacrificed Mori#ud;ody eight ,
8/12/2019 M4 Safety Step 4 Sept02
54/113
The Common Technical Document - Safety
2.6.=.= (1)epeat7&ose Toicity Study "o. ,0otiued
&aily &ose ,mg+-g (0ontrol)"um#er of Aimals 2: *: 2: *: 2: *: 2: *:
Bematology
Serum 0hemistry
8rialysis
Orga eightsa ,
8/12/2019 M4 Safety Step 4 Sept02
55/113
The Common Technical Document - Safety
#otes for %able 8.9..
(1) %he tables should be nu$bered consecutivel: 8.9..! 8.9..! 8.9..0 etc.
(2) %here should be one table for each of the repeat-dose toxicit studies specified b "0;
8/12/2019 M4 Safety Step 4 Sept02
56/113
The Common Technical Document - Safety
2.6.=.> (1)/eotoicity) ' %itro eport Title) Test Article) (2)
Test for 'ductio of) "o. of 'depedet Assays) Study "o.Strais) "o. of eplicate 0ultures) $ocatio i 0T&)Vol. SectionMeta#oliig System) "o. of 0ells Aalyed+0ulture)%ehicles) !or Test Article) !or Positive 0otrols) /$P 0ompliace)
Treatmet) &ate of Treatmet)0ytotoic *ffects)/eotoic *ffects)
2etabolicctivation
%estrticle
0oncentration or,ose /evel( (3) ) _____________ _____________ _____________ ____________ _____________
?ithoutctivation
(0)?ith
ctivation
Notes: (1) The tables should be numbered consecutiely: 2!!9!, 2!!9!
8/12/2019 M4 Safety Step 4 Sept02
57/113
The Common Technical Document - Safety
2.6.=.? (1)/eotoicity) ' %ivo eport Title) Test Article) (2)
Test for 'ductio of) Treatmet Schedule) Study "o.Species+Strai) Samplig Time) $ocatio i 0T&)Vol. SectionAge) Method of Admiistratio)0ells *valuated) %ehicle+!ormulatio) /$P 0ompliace)
"o. of 0ells Aalyed+Aimal) &ate of &osig)Special !eatures)Toic+0ytotoic *ffects)/eotoic *ffects)*videce of *posure)
%est rticle,ose($g@4g)
#o. ofni$als ______________ ______________ ______________ _____________
Notes: (1) The tables should be numbered consecutiely: 2!!9!;, 2!!9!;
8/12/2019 M4 Safety Step 4 Sept02
58/113
The Common Technical Document - Safety
2.6.=.1@ (1)0arciogeicity eport Title) Test Article) (2)
Species+Strai) &uratio of &osig) Study "o.'itial Age) Method of Admiistratio) $ocatio i 0T&)Vol. Section&ate of !irst &ose) %ehicle+!ormulatio)
Treatmet of 0otrols) /$P 0ompliace)
;asis for Bigh7&ose Selectio) (3)Special !eatures)
&aily &ose ,mg+-g (0ontrol)
/ederToico-ietics) A80 , (4)"um#er of AimalsAt Start&ied+Sacrificed Mori#udTermial SacrificeSurvival ,
8/12/2019 M4 Safety Step 4 Sept02
59/113
The Common Technical Document - Safety
2.6.=.1@ (1)0arciogeicity Study "o. ,0otiued
&aily &ose ,mg+-g (0ontrol) (0ontrol)"um#er *valuated"um#er of Aimals
with "eoplastic $esios) (')"oteworthy !idigs)/ross PathologyBistopathology 7 "o7"eoplastic$esios
2: *: 2: *: 2: *: 2: *: 2: *:
- #o noteworth findings.5 - p6.7 55 - p6.1
Th C T h i l D t S f t
8/12/2019 M4 Safety Step 4 Sept02
60/113
The Common Technical Document - Safety
#otes for %able 8.9..1.
(1) %ables should be nu$bered consecutivel: 8.9..1! 8.9..1! ! etc. %here should be one table for each carcinogenicit stud.
(2) "nternational #onproprietar #a$e ("##).
(3) *ro$ "0;
8/12/2019 M4 Safety Step 4 Sept02
61/113
The Common Technical Document Safety
8/12/2019 M4 Safety Step 4 Sept02
62/113
The Common Technical Document - Safety
2.6.=.12 (1)eproductive ad &evelopmetal Toicity 7 eport Title ) Test Article) (2)!ertility ad *arly *m#ryoic&evelopmet to 'mplatatio (3)
&esig similar to '0B (.1.1C &uratio of &osig) 2: Study "o.Species+Strai) &ay of Matig) (&) *: $ocatio i 0T&)Vol. Section'itial Age) &ay of 07Sectio)
&ate of !irst &ose) Method of Admiistratio) /$P 0ompliace)Special !eatures) %ehicle+!ormulatio)"o O#served Adverse7*ffect $evel)
!@Males)!@!emales)!1$itters)
&aily &ose ,mg+-g @ ,0otrol
Males %oxico4inetics: 0 ( ) (0)
#o. Evaluated#o. ,ied or Sacrificed 2oribund0linical bservations#ecrops bservationsod ?eight (Aa)*ood 0onsu$ption (Aa)2ean #o. ,as 'rior to 2ating#o. of 2ales that 2ated#o. of *ertile 2ales (4)
- #o noteworth findings. 3 2ild 332oderate 3332ar4ed ()(9)5 - p6.7 55 - p6.1
a - fter B wee4s of dosing. *or controls! group $eans are shown. *or treated groups! percent differences fro$ controls are shown. Statisticalsignificance is based on actual data (not on the percent differences).
(0ontinued)
59
The Common Technical Document Safety
8/12/2019 M4 Safety Step 4 Sept02
63/113
The Common Technical Document - Safety
2.6.=.12 (1)eproductive ad &evelopmetal Toicity Study "o. ,0otiued
&aily &ose ,mg+-g @ ,0otrol
!emales %oxico4inetics: 0 ( ) (0)
#o. Evaluated#o. ,ied or Sacrificed 2oribund0linical bservations#ecrops bservations're$ating od ?eight (Aa)
8/12/2019 M4 Safety Step 4 Sept02
64/113
The Common Technical Document - Safety
#otes for %ables 8.9..18! 8.9..1= and 8.9..1B
(1) "f there are $ultiple studies of this tpe! the tables should be nu$bered consecutivel: 8.9..18! 8.9..18! 8.9..1=! 8.9..1=! etc.
(2) "nternational #onproprietar #a$e ("##).
(3) "f a $odified stud design is used! tables should be $odified accordingl.
(4) Stead-state 0! 0$ax! or other toxico4inetic infor$ation supporting the stud. "f the infor$ation is fro$ a separate stud! the Stud #u$bershould be given in a footnote.
(5) 'SS"/E '+ESE#%%"#S * %;E +ES/%S +E S;?# "# %;ESE %E2'/%ES. ,% '+ESE#%%"# S;/, E */EC"/E#, ''+'+"%E 00+,"#< % '%"2/ S%%"S%"0/ #/>S"S #, %;E ,ES". "f additional para$etersshowed drug-related changes! these should be added to the tables. *ootnotes should be used as needed to provide additional infor$ation aboutthe tests or the results.
(6) r other scale as appropriate.
(9) 2ethods of statistical analsis should be indicated.
() ,a of $ating should be indicated& e.g.! ,a or ,a 1
61
The Common Technical Document - Safety
8/12/2019 M4 Safety Step 4 Sept02
65/113
The Common Technical Document Safety
2.6.=.13 (1)eproductive ad &evelopmetal Toicity 7 eport Title) Test Article) (2)*ffects o *m#ryo7!etal&evelopmet (3)
&esig similar to '0B (.1.3C &uratio of &osig) Study "o.&ay of Matig) (&)
Species+Strai) &ay of 07Sectio) $ocatio i 0T&)Vol. Section'itial Age) Method of Admiistratio)&ate of !irst &ose) %ehicle+!ormulatio) /$P 0ompliace)Special !eatures)"o O#served Adverse7*ffect $evel)
!@!emales)!1$itters)
&aily &ose ,mg+-g @ ,0otrol
&ams+&oes) %oxico4inetics: 0 ,(0)
#o. 'regnant#o. ,ied or Sacrificed 2oribund#o. borted or with %otal +esorption of /itter0linical bservations#ecrops bservationsod ?eight (Aa)*ood 0onsu$ption (Aa)2ean #o. 0orpora /utea2ean #o. "$plantations2ean A 'rei$plantation /oss
(4)
- #o noteworth findings. 3 2ild 332oderate 3332ar4ed () < D
8/12/2019 M4 Safety Step 4 Sept02
66/113
The Common Technical Document Safety
2.6.=.13 (1)eproductive ad &evelopmetal Toicity Study "o. ,0otiued
&aily &ose ,mg+-g @ ,0otrol
/itters: #o. /itters Evaluated#o. /ive *etuses
2ean #o. +esorptions#o. of /itters with ,ead *etuses2ean A 'osti$plantation /oss2ean *etal od ?eight (g)*etal Sex +atios*etal no$alies:
8/12/2019 M4 Safety Step 4 Sept02
67/113
he Common echnical ocument Safety
2.6.=.1( (1)eproductive ad &evelopmetal Toicity 7 eport Title) Test Article) (2)*ffects o Pre7 ad Postatal&evelopmet4 'cludig Materal !uctio (3)
&esig similar to '0B (.1.2C &uratio of &osig) Study "o.&ay of Matig) (&)
Species+Strai) Method of Admiistratio) $ocatio i 0T&)Vol. Section'itial Age %ehicle+!ormulatio)&ate of !irst &ose) $itters 0ulled+"ot 0ulled) /$P 0ompliace)Special !eatures)"o O#served Adverse7*ffect $evel)
!@!emales)!1Males)!1!emales)
&aily &ose ,mg+-g @ ,0otrol
**e$ales: %oxico4inetics: 0 ( ) (0)
#o. 'regnant#o. ,ied or Sacrificed 2oribund#o. borted or with %otal +es. f /itter0linical bservations#ecrops bservations
8/12/2019 M4 Safety Step 4 Sept02
68/113
f y
2.6.=.1( (1)eproductive ad &evelopmetal Toicity Study "o. ,0otiued
&aily &ose ,mg+-g @ ,0otrol
*1/itters:('reweaning)
*12ales:
('ostweaning)
#o. /itters Evaluated2ean #o. of "$plantations
2ean #o. 'ups@/itter2ean #o. /iveborn 'ups@/itter#o. of /itters with Stillborn 'ups'ostnatal Survival to ,a B'ostnatal Survival to ?eaning#o. of %otal /itter /osses0hange in 'up od ?eightsa(g)'up Sex +atios'up 0linical Signs'up #ecrops bs.
#o. Evaluated 'ostweaning'er /itter
#o. ,ied or Sacrificed 2oribund0linical bservations#ecrops bservationsod-?eight 0hangeb(g)*ood 0onsu$ption (Ac)'reputial SeparationSensor *unction2otor ctivit/earning and 2e$or2ean #o. ,as 'rior to 2ating#o. of 2ales that 2ated#o. of *ertile 2ales
- #o noteworth findings. 3 2ild 332oderate 3332ar4ed ()(9)5 - p6.7 55 - p6.1a - *ro$ birth to weaning.b - *ro$ weaning to $ating.c - t end of postweaning period. *or controls! group $eans are shown. *or treated groups! percent differences fro$ controls are shown.
Statistical significance is based on actual data (not on the percent dif ferences).
65
The Common Technical Document - Safety
8/12/2019 M4 Safety Step 4 Sept02
69/113
f y
2.6.=.1( (1)eproductive ad &evelopmetal Toicity Study "o. ,0otiued
&aily &ose ,mg+-g @ ,0otrol
*1*e$ales:('ostweaning)
*8/itters:
#o. Evaluated 'ostweaning#o. ,ied or Sacrificed 2oribund
0linical bservations#ecrops bservations're$ating od-?eight 0hangea(g)
8/12/2019 M4 Safety Step 4 Sept02
70/113
2.6.=.1( (1)eproductive ad &evelopmetal Toicity Study "o. ,0otiued
&aily &ose ,mg+-g @ ,0otrol
*1*e$ales:('ostweaning)
*8/itters:
#o. Evaluated 'ostweaning#o. ,ied or Sacrificed 2oribund0linical bservations
#ecrops bservations're$ating od-?eight 0hangea(g)
8/12/2019 M4 Safety Step 4 Sept02
71/113
2.6.=.16 $ocal Tolerace (1) Test Article)(2)
Species+Strai
Method ofAdmiistratio
&oses,mg+-g
/eder ad"o. per /roup "oteworthy !idigs
Study"um#er
Notes: (1) ll localtolerance studies should be summari*ed!(2) International Nonproprietary Name (INN)!
68
The Common Technical Document - Safety
8/12/2019 M4 Safety Step 4 Sept02
72/113
2.6.=.1= Other Toicity Studies (1) Test Article)(2)
Species+Strai
Method ofAdmiistratio
&uratioof &osig
&oses,mg+-g
/eder ad"o. per /roup "oteworthy !idigs
Study"um#er
Notes: (1)ll supplementary to-icity studies should be summari*ed!(2) International Nonproprietary Name (INN)!
69
8/12/2019 M4 Safety Step 4 Sept02
73/113
The Common Technical Document - Safety
APPENDIXC
The Nonclinical Tabulated Summaries - Examples
The Common Technical Document - Safety
8/12/2019 M4 Safety Step 4 Sept02
74/113
EC2'/E
2.6.3.1 Pharmacology Overview Test Article) 0uritol Sodiu$
Type of StudyTestSystem
Method ofAdmiistratio
Testig!acility
Study"um#er
$ocatio%ol. Sectio
1.1 Primary Pharmacodyamicsntiviral activit vs. VVntiviral activit vs. VVntiviral activit vs. ;SVntiviral activit vs. 02Vntiviral activit vs. VVntiviral activit vs. SVV
;u$an e$bronic lungfibroblasts0linical isolates;u$an e$bronic lungfibroblasts;u$an e$bronic lungfibroblasts"0+ $ice
frican
8/12/2019 M4 Safety Step 4 Sept02
75/113
The Common Technical Document - Safety
8/12/2019 M4 Safety Step 4 Sept02
76/113
2.6..1 Pharmaco-ietics Overview Test Article) 0uritol Sodiu$
Type of Study
TestSystem
Method ofAdmiistratio
Testig!acility
Study"um#er
$ocatio%ol.Sectio
A#sorptiobsorption and excretionbsorption and excretionbsorption and excretion
+ats,ogs2on4es
8/12/2019 M4 Safety Step 4 Sept02
77/113
2.6..3 Pharmaco-ietics) A#sorptio after a Sigle &ose Test Article) 0uritol Sodiu$$ocatio i 0T& Volu$e 1! SectionStudy um#er F71B
Species Mouse at &og Mo-ey Buma/eder ,M+! + "um#er of aimals B2 =2 B* 82 92!eedig coditio *ed *asted *asted *ed *asted%ehicle+!ormulatio Suspension
1A acaciaSuspension1A acacia
0apsule Suspension1A acacia
%ablet
Method of Admiistratio
8/12/2019 M4 Safety Step 4 Sept02
78/113
Format A
2.6.. Pharmaco-ietics) Orga &istri#utio Test Article) 0uritol Sodiu$
$ocatio i 0T&) Vol. 81! SectionStudy "o. F78
Species) +at/eder ,M+!+"um#er of aimals) =2@each ti$e point!eedig coditio) *asted%ehicle+!ormulatio) Solution@?aterMethod of Admiistratio) ral
8/12/2019 M4 Safety Step 4 Sept02
79/113
Alternate Format B
2.6.. Pharmaco-ietics) Orga &istri#utio Test Article) 0uritol Sodiu$
$ocatio i 0T&) Vol. 81! SectionStudy "o. F78
Species) +at/eder ,M+! + "um#er of aimals) =2@each ti$e point!eedig coditio) *ed%ehicle+!ormulatio) Solution@SalineMethod of Admiistratio) "ntravenous
&ose ,mg+-g) 1adiouclide) #on-labeled co$poundSpecific Activity) 7Aalyte+Assay) nchanged co$pound ($cg@$/)@;'/0
Samplig time) 1 $in! 1! B! G! 8B! BG! F9! and 19G hr 01hr $ast time7poitTissues+orgas coc. T+P1 coc. T+P1 Time A80 t1+2
Beart 1.B .G .BB 88 BG 7.= =.=$iver B.7 9 1.G7 F8.7 BG 8F 71.5idey 8.G .8 1. 7=.7 BG 189 =9.=Splee 9.7 G.9 =.7 17 BG B1 B9.F
Additioal iformatio)
19Tissue:+9Plasma:
EC2'/E
77
The Common Technical Document - Safety
8/12/2019 M4 Safety Step 4 Sept02
80/113
2.6..6 Pharmaco-ietics) Protei ;idig Test Article) 0uritol Sodiu$
Study system) "n vitroTarget etity4 Test system ad method) 'las$a!ltrafiltration
Species 0oc. tested < ;oud
Study "o.
$ocatio i 0T& %ol. Sectio
at 1 - 1u2 G8.1 - G7.B F7=1 81
&og 1 - 1u2 G=.7 - GG.8 F7=1 81
Buma 1 - 1u2 7.8 - F.B F9-1=-= B7
Additioal 'formatio)
78
EC2'/E
The Common Technical Document - Safety
8/12/2019 M4 Safety Step 4 Sept02
81/113
2.6..= Pharmaco-ietics) Study i Pregat or "ursig Aimals Test Article) 0uritol Sodiu$
$ocatio i 0T&) Vol. 88! SectionPlacetal trasfer Study "o.F78Species) +at/estatio day + "um#er of aimals) 1B and 1F das gestation@= ani$als at each ti$e point%ehicle+!ormulatio) Solution@?aterMethod of Admiistratio) ral gavage&ose ,mg+-g) 7Aalyte) %otal radioactivit! 1B0
Assay) /S0Time ,hr 1( days+3@ mi 1( days+2( hr 1? days+3@ mi 1? days+2( hr 0ocetratio + Amout ,< of dose
Materal plasma 18.B .=8 1=.F .=8Placeta =.G .1B =.= .=8Amiotic fluid . .B .B .1=hole fetus .7B .= .=F .1
Additioal 'formatio)2aternal blood! liver! 4idne! ovar! uterus were also exa$ined but not shown.
$ocatio i 0T&) Vol. 88 Section*cretio ito mil- Study "o. F7=Species) +at$actatig date + "um#er of aimals) da @=!eedig coditio) *ed%ehicle+!ormulatio) Solution@?ater
Method of Admiistratio) ral gavage&ose ,mg+-g) 7Aalyte) %otal radioactivit! 1B0Assay) /S0
Time 9hr: 1 2 ( 6 > 2(0ocetratio)
Mil-) .9 .G 1. 1.1 1.= .B
Plasma) 1.7 1.B 1.8 .G .9 .1
Mil- + plasma) .B .7 .G= 1.B 8.8 B.
"eoates
Additioal 'formatio)
EC2'/E
79
The Common Technical Document - Safety
8/12/2019 M4 Safety Step 4 Sept02
82/113
2.6..? Pharmaco-ietics) Meta#olism In Vivo Test Article) 0uritol Sodiu$
/eder ,M+! + "um#er of aimals) ats) B2 &ogs) =* Bumas) G2!eedig coditio) *ed%ehicle+!ormulatio) ats) Solution@water &ogs) 0apsules Bumas) 7-$g tabletsMethod of Admiistratio) ats)
8/12/2019 M4 Safety Step 4 Sept02
83/113
2.6..13 Pharmaco-ietics) *cretio Test Article) 0uritol Sodiu$
Species +at +at ,og ,og/eder ,M+! + "um#er of aimals B2 B2 =2 =2!eedig coditio *asted *asted *asted *asted%ehicle+!ormulatio Solution
?ater
Solution
Saline
0apsule Solution
SalineMethod of Admiistratio ral "ntravenous ral "ntravenous&ose ,mg+-g 1 7 1 7Aalyte %+a %+a %+a %+a
Assay /S0 /S0 /S0 /S0*cretio route 8rie !eces Total 8rie !eces Total 8rie !eces Total 8rie !eces Total Time
@ 7 2( hr@ 7 (> hr@ 7 =2 hr@ 7 ?6 hr
89==1=1
797979
G=F7FFG
8888G8F
9=9F
G7F9FGFF
8878989
8F97=B
BFFFF
1
8=8G8F8F
B8G8=
97F91118
Study um#er F718 F7179$ocatio i 0T& Volu$e 8! Section Volu$e 8! Section
Additioal 'formatio)
a - %otal radioactivit& percent recover!1B
0
EC2'/E
81
The Common Technical Document - Safety
EC2'/E
8/12/2019 M4 Safety Step 4 Sept02
84/113
2.6..1( Pharmaco-ietics) *cretio ito ;ile Test Article) 0uritol Sodiu$
Species at at/eder ,M+! + "um#er of aimals B2 B2!eedig coditio *asted *asted%ehicle+!ormulatio Solution
?ater
Solution
SalineMethod of Admiistratio ral "ntravenous&ose ,mg+-g 1 7Aalyte %+a %+a
Assay /S0 /S0*cretio route ;ile 8rie Total ;ile 8rie Total Time @ 7 2 hr
@ 7 ( hr@ 7 > hr@ 7 2( hr@ 7 (> hr
=798FG=
---F1
=798G9F=
7G8G9GGG
---
1111
7G8G9FGFF
Study um#er F719$ocatio i 0T& Volu$e 8! Section
a 7 Total radioactivityF percet recovery4 1(0
82
EC2'/E
The Common Technical Document - Safety
EC2'/E
8/12/2019 M4 Safety Step 4 Sept02
85/113
2.6.=.1 Toicology Overview Test Article)0uritol Sodiu$
Type of StudySpecies adStrai
Method ofAdmiistratio
&uratioof &osig &oses ,mg+-ga
/$P0ompliace
Testig!acility
Study"um#er
$ocatio%ol.Sectio
Sigle7&oseToicity
0,-1 2ice
?istar +ats
es
>es
>es>es
Sponsor "nc.
0+ 0o.
Sponsor "nc.0+ 0o.
F9B9
F9B
F97F971
1
1
11
epeat7&oseToicity
0,-1 2ice
?istar +ats
eagle ,ogs
0no$olgus2on4es
,iet
,ietes>es
#o
0+ 0o.
Sponsor "nc.Sponsor "nc.Sponsor "nc.
Sponsor "nc.
Sponsor "nc.Sponsor "nc.
0+ 0o.
FB1G
FB1FFBFB81B
F71
FB8F9B1
FBG
8
==B
7
9
G
/eotoicity S.tphi$uriu$and E. coli
;u$an/$phoctes
?istar +ats
"n Vitro
"n Vitro
es
>es
>es
Sponsor "nc.
0+ 0o.
Sponsor "nc.
F91G
F9=B
F9=
F
F
F
a - nless otherwise specified. *or Single-,ose %oxicit and +epeat-,ose %oxicit! the highest #E/ (#o bserved dverse-Effect /evel)is underlined.
(0ontinued)
EC2'/E
The Common Technical Document - Safety
EC2'/E
8/12/2019 M4 Safety Step 4 Sept02
86/113
2.6.=.1 Toicology Overview ,0otiued Test Article)0uritol Sodiu$
Type of Study
Species adStrai
Method ofAdmiistratio
&uratioof &osig &oses ,mg+-g
/$P0ompliace
Testig!acility
Study"um#er
$ocatio%ol.Sectio
0arciogeicity 0,-1 2ice
?istar +ats
,iet
es
>es
0+ 0o.
Sponsor "nc.
F718
F71=
1
18
eproductioToicity
?istar +ats?istar +ats#? +abbits?istar +ats
8/12/2019 M4 Safety Step 4 Sept02
87/113
EC2'/E
2.6.=.2 Toico-ietics Overview of Toico-ietics Studies Test Article) 0uritol Sodiu$
Type of StudyTestSystem
Method ofAdmiistratio &oses ,mg+-g
/$P0ompliace
Study"um#er
$ocatio%ol. Sectio
%hree-$onth range-finding stud%wo-wee4 toxicit studSix-$onth toxicit studne-$onth toxicit stud#ine-$onth toxicit stud0arcinogenicit stud0arcinogenicit stud%oxico4inetics stud
2ice+ats+ats,ogs,ogs2ice+ats+abbits
,ietes>es>es#o
FB1GFBF71FB8F9B1F718F71=F8=1
8 = 7 9 11819
85
The Common Technical Document - Safety
EC2'/E
8/12/2019 M4 Safety Step 4 Sept02
88/113
2.6.=.3 Toico-ietics Overview of Toico-ietics &ata Test Article)0uritol Sodiu$
Steady7State A80 ,mcg7hr+ml
&aily &ose,mg+-g)
Micea
M !ats#
M ! &ogsc!emalea##its# Bumasf
1 7 1 8 87 B
1 18 9 G
= B1
1
F 87
8=
=
798.7187=B
=7 B18
G17
B BG 1=7
7
87d! 8e
9G F
8d! 88e
8 G7
18
B
7F18B
8!1=
B!F7G!8B1
1!G
=!FG!9G
187 8 87 =8
18 1F 8B =81
__________a - "n diet.b - gavage.
c - "n capsules. 2ales and fe$ales co$bined.d - Six-$onth toxicit stud.e - 0arcinogenicit stud.f - 'rotocol 1B-.
86
EC2'/E
The Common Technical Document - Safety
8/12/2019 M4 Safety Step 4 Sept02
89/113
*GAMP$*
2.6.=.3 Toico-ietics Overview of Toico-ietics &ata Test Article ) 0uritol Sodium
.1
1
1
1
1
.1 .1 1 1 1
&ose ,mg+-g.
;u$ans
2ale 2ice
*e$ale 2ice
2ale +ats
*e$ale +ats
,ogs
Stead-state 08Bhrvalues of unchanged 22-1GG1 in hu$ans after repeated oral ad$inistration of 1! 8.7! and 7 $g ,! in co$parison with thosein $ice in the carcinogenicit stud! rats in the 9-$onth toxicit stud! and dogs in the F-$onth toxicit stud.
A80
2(hr
,ughr+ml.
87
The Common Technical Document - Safety
EC2'/E
8/12/2019 M4 Safety Step 4 Sept02
90/113
2.6.=.( Toicology &rug Su#stace Test Article) 0uritol Sodiu$
;atch "o. Purity ,
8/12/2019 M4 Safety Step 4 Sept02
91/113
2.6.=. Sigle7&ose Toicity Test Article)0uritol Sodiu$
Species+Strai
Method ofAdmiistratio,%ehicle+!ormulatio
&oses,mg+-g
/ederad "o.per /roup
O#servedMaimum "o7$ethal &ose,mg+-g
Approimate$ethal&ose ,mg+-g "oteworthy !idigs
Study"um#er
0,-1 2ice
8/12/2019 M4 Safety Step 4 Sept02
92/113
2.6.=.6 epeat7&ose Toicity "o7Pivotal Studies Test Article)0uritol Sodiu$
Species+Strai
Method ofAdmiistratio,%ehicle+
!ormulatio
&uratioof &osig
&oses,mg+-g
/ederad "o.per /roup
"OA*$a
,mg+-g "oteworthy !idigsStudy"um#er
0,-1 2ice ,iet = 2onths ! 98.7!87! 1!B! and
12! 1* 2:B*: 1
B: /ower bod weights& gastric
erosions@ulcers in so$e $ice.: B2 and 9* died@ sacrificed&lower bod weights& single-cell necrosisin liver.
FB1G
?istar+ats
,iet
8/12/2019 M4 Safety Step 4 Sept02
93/113
2.6.=.=A epeat7&ose Toicity eport Title) 22-1GG1: %hree-2onth ral %oxicit Stud in +ats Test Article)0uritol Sodiu$
Species+Strai)?istar +ats &uratio of &osig)= 2onths Study "o.FB81B'itial Age)7 ?ee4s &uratio of Postdose)1 2onth $ocatio i 0T&)Vol. B! Section&ate of !irst &ose)17 Kan FB Method of Admiistratio)esSpecial !eatures)#one
"o O#served Adverse7*ffect $evel)8 $g@4g
&aily &ose ,mg+-g (0ontrol) 8 9 1G"um#er of AimalsToico-ietics) A80 ,mcg7hr+ml)&ay 1&ay 2>&ay ?@"oteworthy !idigs&ied or Sacrificed Mori#ud;ody eight ,
8/12/2019 M4 Safety Step 4 Sept02
94/113
2.6.=.=A epeat7&ose Toicity Study "o. ?(21( ,0otiued
&aily &ose ,mg+-g (0ontrol) 8 9 1G
"um#er of Aimals
Bematology
Bemoglo#i ,g+dl*rythrocyte 0out ,1@6+mm3
M0B
M0B0
Platelet 0out ,1@3+mm3
Serum 0hemistry
0reatiie ,'8+$
Proteis g+dl
0holesterol ,mg+dl
A$T ,'8+$
AST ,'8+$
;iliru#i ,mg+dl
0alcium ,m*D+$
Phosphorus ,m*D+$
8rialysis
Protei 0oc. ,mg+dl
pB
/lucose ,mg+dl
8rie %olume ,ml
2:=
17.GG.1
-
-
GB9
.
-
F9
9
GG
.1G
-
F.=
89
.7
-
-
*:=
17.-
88
=B
FF
.
9.
-
79
F8
.8
1.
-
BF
-
1G
2:8
17..F
-
-
G87
.
-
G9
95
F9
.1
-
F.=
18
.7
-
-
*:8
1B.F-
81
=B
G1B
.
9.9
-
78
F
.8
1.G
-
=B
-
1G
2:8
17.GG.1
-
-
F1B
.
-
F
775
G5
.1G
-
F.=
18=
.8
-
-
*:8
1B.9-
88
=B
G79
.
9.9
-
B5
GB5
.8
1.G
-
7B
-
8
19
2:=
1B.5.B5
-
-
F=15
1.15
-
175
7=5
G75
.8855
-
G.85
1895
9.=55
-
-
*:=
1=.15-
1F5
=5
F115
1.15
7.55
-
7G
F=
.8955
F.G55
-
885
-
FG55
185
- #o noteworth findings.,unnettLs %est: 5- p6.7 55- p6.1
(0ontinued)
92
8/12/2019 M4 Safety Step 4 Sept02
95/113
The Common Technical Document - Safety
EC2'/E M8
8/12/2019 M4 Safety Step 4 Sept02
96/113
2.6.=.=; epeat7&ose Toicity eport Title) 22-1GG1:ne-2onth ral %oxicit Stud in ,ogs Test Article)0uritol Sodiu$
Species+Strai)eagle ,ogs &uratio of &osig)1 2onth Study "o.FB8'itial Age)7-9 2onths &uratio of Postdose)#one $ocatio i 0T&)Vol. 9! Section&ate of !irst &ose)8 *eb FB Method of Admiistratio)ral
%ehicle+!ormulatio)esSpecial !eatures);epatic enN$e induction evaluated at ter$ination.
"o O#served Adverse7*ffect $evel)1 $g@4g
&aily &ose ,mg+-g (0ontrol) 1 B 1
"um#er of Aimals
Toico-ietics) A80 ,mcg7hr+ml)
&ay 1
&ay 2>
"oteworthy !idigs
"o. &ied or Sacrificed Mori#ud
;ody eight ,A /eotoicity) ' %itro eport Title) 22-1GG1: $es +everse-2utation Stud in Test Article) 0uritol Sodiu$ Sal$onella and E. 0oli
Test for 'ductio of)+everse $utation in bacterial cells "o. of 'depedet Assays)8 Study "o.F999FStrais)S. tphi$uriu$ and E. coli "o. of eplicate 0ultures)= $ocatio i 0T&)Vol. 1! SectionMeta#oliig System)roclor-induced rat liver SF4.1A "o. of 0ells Aalyed+0ulture)-%ehicles) Test Article),2S Positive 0otrols),2S /$P 0ompliace)>esTreatmet)'late incorporation for BG hr. &ate of Treatmet)*eb. 1FF9
0ytotoic *ffects) #one./eotoic *ffects)#one.
2etabolicctivation
%estrticle
,ose /evel($cg@plate)
ssa M1+evertant 0olon 0ounts (2ean OS,)
% FG % 1 % 17=7 % 17= ?'8 uvr
?ithoutctivation
,2S22-1GG1
8-#itrofluoreneSodiu$ aNideF-$inoacridine22S
1 $cl@plate=18.7987187877a
8118.7 $cl@plate
8B O F8B O 9=8 O F= O B8 O 7= O =9F9
18F O B18G O 1117= O F178 O 181B O 91= O 81
7B8
17 O B18 O BF O 8F O =F O =17 O 1
B9G
B O 8B O 8G O 8F O 87 O 1 O 8
717
1 O =1B O 81 O 71G O B1F O 11= OB
7=
?ithctivation
,2S22-1GG1
8-$inoanthracene
1 $cl@plate=18.798718787
7
a
8.71
8 O 9=1 O B= O 1== O 8=7 O G
=1 O B1778
191 O 181B8 O G179 O 1717= O 1=19 O B
17= O 71BG
18 O 718 O 71 O 81= O =1 O 8
F O B81B
7 O 1B O 8F O 7G O 8G O 8
O 191
81 O G1 O =8= =1G O =1F O 7
1 OB
=99a - 'recipitation.
96
8/12/2019 M4 Safety Step 4 Sept02
99/113
The Common Technical Document - Safety
EC2'/E M1
8/12/2019 M4 Safety Step 4 Sept02
100/113
2.6.=.?A /eotoicity) ' %ivo eport Title) 22-1GG1: ral 2icronucleus Stud in +ats Test Article) 0uritol Solution
Test for 'ductio of)one-$arrow $icronuclei Treatmet Schedule)%hree dail doses. Study "o)F99G=Species+Strai)?istar +ats Samplig Time)8B hr after last dose. $ocatio i 0T&)Vol. 1! SectionAge)7 ?ee4s Method of Admiistratio)
8/12/2019 M4 Safety Step 4 Sept02
101/113
2.6.=.?; /eotoicity) ' %ivo eport Title) 22-1GG1: ral ,# +epair Stud in +ats Test Article) 0uritol Solution
Test for 'ductio of)nscheduled ,# snthesis Treatmet Schedule)Single dose. Study "o)71FSpecies+Strai)?istar +ats Samplig Time)8 and 19 hr. $ocatio i 0T&)Vol. 11! SectionAge)7 ?ee4s Method of Admiistratio)es"o. of 0ells Aalyed+Aimal)1 &ate of &osig)Kan. 1FF
Special !eatures)#one.Toic+0ytotoic *ffects)#one./eotoic *ffects)#one.*videce of *posure)%oxico4inetics - See Stud #o. FB! %wo-?ee4 ral %oxicit Stud in +ats.
%est rticle,ose
($g@4g)#o. of
ni$als%i$e hr
#uclear2ean O S,
0toplas$2ean O S,
#es &uratio of &osig)
8/12/2019 M4 Safety Step 4 Sept02
109/113
2.6.=.13 eproductive ad &evelopmetal Toicity Study "o. ?=@2>,0otiued
&aily &ose ,mg+-g @ ,0otrol 1 2
/itters: #o. /itters Evaluated#o. /ive *etuses
2ean #o. +esorptions#o. ,ead *etuses2ean A 'osti$plantation /oss2ean *etal od ?eight (g)*etal Sex +atios (A $ales)*etal no$alies:
8/12/2019 M4 Safety Step 4 Sept02
110/113
The Common Technical Document - Safety
2 6 = 1( eproductive ad &evelopmetal Toicity Study "o ?2@1
EC2'/E
8/12/2019 M4 Safety Step 4 Sept02
111/113
2.6.=.1( eproductive ad &evelopmetal Toicity Study "o. ?2@1,0otiued
&aily &ose ,mg+-g @ ,0otrol =. = =@
*1/itters:('reweaning)
*12ales:('ostweaning)
#o. /itters Evaluated2ean #o. 'ups@/itter
2ean #o. /iveborn 'ups@/itter2ean #o. Stillborn 'ups@/itter'ostnatal Survival to ,a B'ostnatal Survival to ?eaning0hange in 'up od ?eightsa(g)'up Sex +atios (A $ales)'up 0linical Signs'up #ecrops bs.
#o. Evaluated 'ostweaning#o. ,ied or Sacrificed 2oribund0linical bservations
#ecrops bservationsod ?eight 0hangeb (g)*ood 0onsu$ption (Ab)'reputial SeparationSensor *unction2otor ctivit/earning and 2e$or2ean #o. ,as 'rior to 2ating#o. of 2ales that 2ated#o. of *ertile 2ales
8=1=.9
1=.7.1--971--
8=--
-817 g----8.B8=8=
811=.G
1=.G.--7G7=--
81--
-1F7----=.=8181
881B.F
1B.9.=--98BF--
88--
-1F7----8.F811F
1711.833
F.B331.G3
--7=571--
17--
-1G95-115----=.78=8
- #o noteworth findings. 3 2ild 332oderate 3332ar4ed
,unnettLs %est 5 - p6.7 55 - p6.1rus4al-?allis with ,unnLs procedure 3 - p6.7 33 - p6.1a - *ro$ birth to weaning.b - *ro$ weaning to $ating. *or controls! group $eans are shown. *or treated groups! percent differences fro$ controls are shown. Statistical
significance is based on actual data (not on the percent differences).(0ontinued)
109
The Common Technical Document - SafetyEC2'/E
8/12/2019 M4 Safety Step 4 Sept02
112/113
f y
2.6.=.1( eproductive ad &evelopmetal Toicity Study "o. ?2@1 ,0otiued
&aily &ose ,mg+-g @ ,0otrol =. = =@
*1*e$ales:
('ostweaning)
*8/itters:
#o. Evaluated 'ostweaning
#o. ,ied or Sacrificed 2oribund0linical bservations#ecrops bservations're$ating od-?eight 0hangea(g)
8/12/2019 M4 Safety Step 4 Sept02
113/113
,unnettLs %est 5 - p6.7 55 - p6.1a - *ro$ weaning to $atingb - ,uring postweaning period. *or controls! group $eans are shown. *or treated groups! percent differences fro$ controls are shown. Statistical
significance is based on actual data (not on the percent differences). (0ontinued)
EC2'/E
2.6.=.1= Other Toicity Studies Test Article)0uritol Sodiu$
Species+Strai
Method ofAdmiistratio
&uratioof &osig
&oses,mg+-g
/eder ad"o. per /roup "oteworthy !idigs
Study"um#er
Atigeicity
Recommended